Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul 1;39(25):e208.
doi: 10.3346/jkms.2024.39.e208.

Evolution of blaKPC Under the Pressure of Carbapenems and Ceftazidime/Avibactam in a Patient With Persistent Bacteremia Caused by Klebsiella pneumoniae

Eun Jeong Won  1 , Kuenyoul Park  2 , Yun Sil Jeong  1 , Jiyeon Kim  1 , Yunsuk Choi  3 , Sung-Han Kim  4 , Mi-Na Kim  5 , Heungsup Sung  1
Affiliations
Case Reports

Evolution of blaKPC Under the Pressure of Carbapenems and Ceftazidime/Avibactam in a Patient With Persistent Bacteremia Caused by Klebsiella pneumoniae

Eun Jeong Won et al. J Korean Med Sci. .

Abstract

A 30-year-old Korean man with myelodysplastic syndrome admitted hospital due to undifferentiated fever and recurrent skin lesions. He received combination therapy with high doses of meropenem, tigecycline and amikacin, yielding carbapenem resistant Klebsiella pneumoniae (CRKP) harboring K. pneumoniae carbapenemase (KPC)-2 from blood cultures on hospital day (HD) 23. Ceftazidime/avibactam was started at HD 37 and CRKP was eradicated from blood cultures after 5 days. However, ceftazidime/avibactam-resistant CRKP carrying KPC-44 emerged after 26 days of ceftazidime/avibactam treatment and then ceftazidime/avibactam-resistant, carbapenem-susceptible K. pneumoniae carrying KPC-135 was isolated on HD 65. The 3-D homology of KPC protein showed that hot spot changes in the omega loop could be attributed to ceftazidime/avibactam resistance and loss of carbapenem resistance. Whole genome sequencing of serial isolates supported that phenotypic variation was due to clonal evolution than clonal replacement. The treatment regimen was changed from CAZ/AVI to meropenem-based therapy (meropenem 1 g iv q 8 hours and amikacin 600 mg iv per day) starting with HD 72. CAZ/AVI-susceptible CRKP was presented again from blood cultures on HD 84, and the patient expired on HD 85. This is the first Korean report on the acquisition of ceftazidime/avibactam resistance through the emergence of blaKPC variants.

Keywords: 3-D Homology; Carbapenem Resistant Klebsiella pneumoniae; Carbapenemase; Ceftazidime/Avibactam; Klebsiella pneumoniae; Whole-Genome Sequencing; blaKPC.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Chronological changes in the susceptibility of Klebsiella pneumoniae (KPN) isolated during the course of this case (being treated with ceftazidime/avibactam and meropenem) to ceftazidime/avibactam and carbapenem. KPN isolates were serially recovered from blood cultures (square), respiratory cultures (circle), and stool cultures (diamond).
KPC = K. pneumoniae carbapenemase.
Fig. 2
Fig. 2. Representative view of the overall KPC-2 or its variants of Klebsiella pneumoniae strains in this study. (A) KPC-2 structure of A5593, (B) KPC-44 structure of A7408, and (C) KPC-135 structure of A8177. The blue dotted circle indicates the omega loop region and the yellow dotted circle indicates the terminal loop.
KPN = K. pneumoniae carbapenemase.
Fig. 3
Fig. 3. Whole-genome sequencing analysis of blood isolates of Klebsiella pneumoniae in this study. Minimum spanning tree based on the phylogeny of 14 isolates using core genome multi-locus sequence typing with eight ST307 domestic and global isolates. The red dotted circle indicates the strains isolated before HD 41 and the blue dotted circle indicates the strains isolated after HD 63, respectively.
HD = hospital day.
See this image and copyright information in PMC

References

    1. Gonçalves Barbosa LC, Silva E Sousa JA, Bordoni GP, Barbosa GO, Carneiro LC. Elevated mortality risk from CRKp associated with comorbidities: systematic review and meta-analysis. Antibiotics (Basel) 2022;11(7):874. - PMC - PubMed
    1. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae . Ann Clin Microbiol Antimicrob. 2017;16(1):18. - PMC - PubMed
    1. Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, et al. Carbapenemase-producing organisms: a global scourge. Clin Infect Dis. 2018;66(8):1290–1297. - PMC - PubMed
    1. Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob Agents Chemother. 2010;54(2):890–897. - PMC - PubMed
    1. Hayden DA, White BP, Bennett KK. Review of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem/cilastatin-relebactam to target Klebsiella pneumoniae carbapenemase-producing enterobacterales. J Pharm Technol. 2020;36(5):202–210. - PMC - PubMed

Publication types

MeSH terms